COVID-19 vaccine development at early stage in India; breakthrough unlikely within a year: Experts
Referring to a vaccine to fight the virus, a PMO statement had said that it is the most pressing need and Indian academia, start-ups and industry have come together in cutting-edge vaccine design and development. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 22, 2020 Category: Pharmaceuticals Source Type: news

ICMR clears hydroxychloroquine for wider usage, but with some riders
According to the new guidelines — which come with caveats — recommended by the joint monitoring group and the national task force set up by ICMR, hydroxychloroquine can be given as a prophylactic for all asymptomatic healthcare workers involved in treating Covid-19, including those in quarantine centres. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 22, 2020 Category: Pharmaceuticals Source Type: news

Cipla and Hetero seek clinical trial waiver for Remdesivir
While all new drugs must undergo trials before getting marketing approval in India, the regulator can grant exemptions in public interest and in cases of national emergency, extreme urgency and epidemics. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 22, 2020 Category: Pharmaceuticals Source Type: news

How one Indian company could be world's door to a COVID-19 vaccine
Serum Institute, the world's largest manufacturer of vaccines, is working on several candidates. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 22, 2020 Category: Pharmaceuticals Source Type: news

First COVID-19 vaccine human trial finds it is safe, induces immune response
In the trial, carried out in 108 healthy adults, the vaccine demonstrated promising results after 28 days, with the final results to be evaluated in six months, the study said. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 22, 2020 Category: Pharmaceuticals Source Type: news

Gilead ’s remdesivir mainly helped healthier Covid-19 patients
The publication also allowed greater insight into which patients seemed to respond best to treatment. The only group to do significantly better on remdesivir were those who were sick enough to need supplemental oxygen, but who weren ’t yet on a ventilator or a heart-lung bypass machine. While the lack of benefit might have stemmed from the limited number of patients in those groups. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 22, 2020 Category: Pharmaceuticals Source Type: news

The Department of Pharmaceuticals proposes to oversee drug regulator
The Cabinet secretary had constituted a committee tasked with reforming the drug regulatory system under the chairmanship of Rajesh Bhushan, who will take over as health secretary from the present health secretary Preeti Sudan after three months. The committee will meet on Friday, according to the order accessed by ET. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 21, 2020 Category: Pharmaceuticals Source Type: news

Strides Pharma to conduct trials in India for potential COVID-19 drug
The Bengaluru-based company has received approval from the Drug Controller General of India to conduct trials of favipiravir in the country, Strides Founder and Non-Executive Chairman Arun Kumar said on a post-earnings conference call, without giving any more details. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 20, 2020 Category: Pharmaceuticals Source Type: news

​US pharma firm Gilead Sciences likely to seek nod to market anti-viral drug remdesivir in India
Officials of the Union Health Ministry, along with the Drugs Controller General of India (DCGI) held a discussion with the representatives of Gilead Sciences on Wednesday to prepare a road map for introducing remdesivir in India, sources said. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 20, 2020 Category: Pharmaceuticals Source Type: news

Bharat Bio, Thomas Jefferson varsity to pursue Covid-19 vaccine candidate
The vector used in this new COVID-19 vaccine under accelerated development program is a deactivated rabies vaccine that is known to produce a strong immune response and is approved for the whole population including children and pregnant women, it said. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 19, 2020 Category: Pharmaceuticals Source Type: news

Ahmedabad based Troikaa Pharma receives US patent for pain relief formula
The Department of Science& Technology (India) had recognised Dynapar QPS for the successful commercialisation of indigenous technology by rewarding it with TDB (Technology Development Board) National Award in the year 2015, the company statement added. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 19, 2020 Category: Pharmaceuticals Source Type: news

Restrictions on number of employees, mandatory use of Aarogya Setu, Gurugram issues fresh guideline for offices
“All private offices can operate with upto 50% strength as per requirement, with the remaining persons working from home,” said Gurugram’s District Magistrate Amit Khatri said in an order issued on Wednesday. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 19, 2020 Category: Pharmaceuticals Source Type: news

Dental clinics allowed to operate for emergencies
All routine and elective dental procedures, the ministry said, should be deferred for a later review until new policy guidelines are issued. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 19, 2020 Category: Pharmaceuticals Source Type: news

As demand is high, go for targeted testing: Foundation for Innovative New Diagnostics Chief Access Officer
Testing without symptoms or history of being exposed is wasteful, so there is the controversial idea of “immunity passports” where you test to safeguard the travel industry. But if you have a good diagnostic test that gives you assurance that you had been exposed and you are negative, says FIND Chief Access Officer Sergio Carmona. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 18, 2020 Category: Pharmaceuticals Source Type: news

HIV drug may replace hydroxychloroquine in Covid defence
India's top health research body is reviewing its treatment guidelines for Covid-19 and may drop hydroxychloroquine (HCQ) from the protocol due to increasing doubt over its effectiveness, people in the know told ET. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 18, 2020 Category: Pharmaceuticals Source Type: news

US drugmaker reports promising early results from COVID-19 vaccine test
The Cambridge, Massachusetts-based company said the vaccine candidate, mRNA-1273, appeared to produce an immune response in eight people who received it similar to that seen in people convalescing from the virus. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 18, 2020 Category: Pharmaceuticals Source Type: news

IT solutions provider ESDS launches AA+ Covid 19 testing solution
ESDS said its AA+ COVID-19 Testing Solution indicates whether the patient is suffering from COVID-19 in less than 5 minutes.It further stated the solution is a complete contactless testing procedure, through which health officials can collect the Chest X-ray reports, upload them on a web browser and click on the submit button. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 17, 2020 Category: Pharmaceuticals Source Type: news

Cipla submits application with USFDA for generic version of asthma drug
Drug major Cipla on Monday said it has submitted an application with the US health regulator for a generic version of GSK's Advair Diskus, which is used in the treatment of asthma and other respiratory disorders. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 17, 2020 Category: Pharmaceuticals Source Type: news

Cocktail of antibodies may block coronavirus infection, shows study
The study, published in the journal Nature, noted that antibodies, produced by the immune system of recovered people, can neutralise the virus, and help in the development of anti-viral treatments or vaccines. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 17, 2020 Category: Pharmaceuticals Source Type: news

Ashwagandha can be effective COVID-19 preventive drug, finds research by IIT Delhi and Japan's AIST
The drug's development may take some time, and in the current scenario, these natural resources -- Ashwagandha and Propolis -- can offer some preventive or even therapeutic value, according to D Sundar, head of the Delhi Indian Institute of Technology's Biotechnology department. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 17, 2020 Category: Pharmaceuticals Source Type: news

Azim Premji Foundation, NCBS-TIFR, inStem join hands to ramp up Covid-19 testing
The partnership of Azim Premji Foundation, the National Centre for Biological Sciences and the Institute for Stem Cell Science and Regenerative Medicine will enable free-of-cost testing for Covid-19 to a large number of people from disadvantaged and marginalised communities. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 17, 2020 Category: Pharmaceuticals Source Type: news

Coronavirus vaccine from Moderna shows early signs of viral immune response
The study was primarily designed to look at the safety of the shot and showed no major warning signs in a small phase 1 trial, the company said in a statement Monday. The trial is being run with the U.S. government, and Moderna plans to continue advancing it to wider testing. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 17, 2020 Category: Pharmaceuticals Source Type: news

ICMR revises COVID-19 testing strategy, returnees with ILI symptoms will be tested within 7 days
Besides, asymptomatic direct and high-risk contacts of a confirmed case are to be tested once between day five and day 10 of coming in contact, the new document stated. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 17, 2020 Category: Pharmaceuticals Source Type: news

COVID-19: AIIMS Bhopal claims good results in drug trial
The trials of the drug Mycobacterium W (Mw) were conducted on COVID-19 patients at AIIMS Bhopal for the last few days, the official said. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 15, 2020 Category: Pharmaceuticals Source Type: news

Stimulus package can help Biotech sector become self-reliant
Kiran Mazumdar-Shaw said that the world is waiting for a vaccine for COVID-19 but till the time it is developed, there is a need to conduct tests and build a treatment regime to save lives. Indian biotech sector worked quickly and came out with indigenous test kits. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 15, 2020 Category: Pharmaceuticals Source Type: news

Biocon says use of Itolizumab in COVID-19 treatment encouraging
Biocon has witnessed encouraging results in the use of its novel biologic Itolizumab for treating some Covid-19 related conditions, the pharmaceutical company said on Friday. Biocon said the first set of trials using the drug were done in Mumbai and Delhi. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 15, 2020 Category: Pharmaceuticals Source Type: news

USFDA Looks for Ways to Speed up Plant Inspections
The move has been triggered by the shortage of drugs — most of them supplied by Indian generic drug companies — that the US faces during the Covid-19 pandemic. The Indian Pharmaceutical Alliance has asked the FDA last month to find a solution for inspecting the manufacturing plants of its members. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 15, 2020 Category: Pharmaceuticals Source Type: news

'No benefit' in hydroxychloroquine virus treatment: Two studies
The anti-inflammatory has been touted by US President Donald Trump among others as a potential "game changer", after initial studies in lab settings showed it may be able to prevent the virus replicating. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 14, 2020 Category: Pharmaceuticals Source Type: news

Affordable access to Covid-19 drugs: Are voluntary patent licences here to stay?
Remdesivir is presently considered the most promising candidate for the treatment of COVID-19, and is the subject matter of three Indian patents granted in 2016, 2019 and early 2020 respectively. Through the licenses, the licensee companies will be provided transfer of technology and would be able to set their own prices for the drug. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 14, 2020 Category: Pharmaceuticals Source Type: news

Health groups ask India to rescind Gilead's patents for COVID-19 drug remdesivir
Drug patents in India are an important issue as many countries depend on generic drugmakers to make and sell cheaper versions of critical drugs to them. Gilead's three patents in India for remdesivir stem from 2009 when the drug was in development to treat Ebola. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 13, 2020 Category: Pharmaceuticals Source Type: news

More companies in talks for Remdesivir licence
This week, Cipla, Jubilant Life Sciences, Hetero and Mylan signed non-exclusive licensing agreements for the antiviral drug which received emergency use authorisation from the US Food and Drug Administration after trial results showed that it halved the recovery time to five days for moderately affected patients. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 13, 2020 Category: Pharmaceuticals Source Type: news

India to test four drugs as part of WHO trial
Potential anti-viral agents remdesivir, chloroquine/hydroxychloroquine, lopinavir-ritonavir and lopinavir-ritonavir with interferon will be evaluated as part of the trial, the Indian Council of Medical Research said on Wednesday. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 13, 2020 Category: Pharmaceuticals Source Type: news

‘We will ensure Remdesivir supply when India wants it’
Hyderabad based generic pharmaceutical company Hetero Labs is working on a “war footing” to make remdesivir available for Covid-19 patients in India, having entered into a licensing agreement with US-based Gilead Sciences to manufacture and market the antiviral drug in 127 countries, Hetero Labs’ managing director Vamsi Krishna Bandi told ET’s Teena Thacker in an i nterview. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 13, 2020 Category: Pharmaceuticals Source Type: news

COVID-19: Guidelines issued for RT-PCR based pool sampling of migrants, returnees from abroad
The same testing technique would also be used for monitoring in green zones districts which have reported no cases till now or in the last 21 days, the Union Health ministry said while issuing 'Guidelines for RT-PCR based pooled sampling for migrants/returnees from abroad/green zones' on Thursday. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 13, 2020 Category: Pharmaceuticals Source Type: news

Modi's 'self-reliance' call need of the hour: Pharma industry
During these unprecedented times, the pharmaceutical industry has worked with the government in an integrated manner and continued to operate with vigour to drive local expertise and truly live up to its title as the 'Pharmacy of the World', the prime minister added. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 12, 2020 Category: Pharmaceuticals Source Type: news

Celkon forays into healthcare products
Mobile handset maker Celkon announced that it will enter the healthcare products sector with a range of products under ‘Celkon Health’ brand to tackle the Covid-19 pandemic. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 12, 2020 Category: Pharmaceuticals Source Type: news

Gilead sign licensing deal for Remdesivir with three Indian companies
ET had reported on May 5 that Gilead Sciences was in talks with several Indian companies including Jubilant Life Sciences for a licensing deal. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 11, 2020 Category: Pharmaceuticals Source Type: news

Goa diagnostic company ’s tuberculosis device could help scale up Covid-19 testing
Truenat, a product of Molbio Diagnostics that ’s been used to detect tuberculosis, also speeds up the reverse transcription polymerase chain reaction (RT-PCR) technique, which detects the presence of the coronavirus. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 11, 2020 Category: Pharmaceuticals Source Type: news

Glenmark initiates Phase 3 clinical trials on Favipiravir to check efficacy on COVID-19 patients
The Mumbai-based company had received approval from Drug Controller General of India (DCGI) last month to conduct clinical trials of Favipiravir antiviral tablets for the treatment of COVID-19 patients. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 11, 2020 Category: Pharmaceuticals Source Type: news

Treating Covid-19: Clinical trials using arthritis drug get nod
“The CDSCO (Central Drugs Standard Control Organisation) has approved a vital randomised controlled trial on Covid-19 treatment with a biological called tocilizumab, in the first proposed multi-centre trial with the drug in India,” said Dr AS Soin, national lead investigator for the trial. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 11, 2020 Category: Pharmaceuticals Source Type: news

Vaccine should be feasible against virus, one year target looks reasonable: K VijayRaghavan
The government ’s principal scientific advisor says until we have a vaccine and it is distributed and given to people, we have to make sure that we take care to follow the five mantras — hygiene, wear masks, practice social distancing, test and track (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 10, 2020 Category: Pharmaceuticals Source Type: news

Government picks IIT, Bennett University proposals in war on Covid
In order to urgently develop “safe and effective biomedical solutions” against Covid-19, the department of biotechnology (DBT) under science ministry has recommended 70 proposals from different institutions, including several IITs, JNU and Bennett University, for funding. These proposals are related to the development of va ccines, devices, diagnostics, therapeutics and other technological interventions. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 10, 2020 Category: Pharmaceuticals Source Type: news

COVID-19 patients can end home isolation after 17 days: Revised guidelines
​​The revised guidelines released by the health ministry reiterated that patients, who are pre-symptomatic or have very mild symptoms, can opt for home isolation if they have the requisite self-isolation facility at their residence so as to avoid contact with other family members. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 10, 2020 Category: Pharmaceuticals Source Type: news

Dr Reddy's recalls 1,752 bottles of heartburn drug in the US
The ongoing Class III recall is on account of "Discolouration" and because the product contains brown pellets, USFDA said. As per the US health regulator, a class III recall is initiated in a situation "in which use of or exposure to a violative product is not likely to cause adverse health consequences". (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 9, 2020 Category: Pharmaceuticals Source Type: news

Mega FDI plan to focus on faster pharma approvals
The govt has begun examining ways to shore up foreign investments, including a fast-track mechanism to clear applications of companies especially in the pharmaceutical sector that are looking at India with the US pushing its companies to relocate from China. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 9, 2020 Category: Pharmaceuticals Source Type: news

Bharat Bio leads CSIR project to develop human antibodies
This programme brings together academia — National Centre for Cell Science, Indian Institute of Technology, Indore, and industry – PredOmix Technologies and Bharat Biotech, in a collaborative mode for a public health emergency. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 8, 2020 Category: Pharmaceuticals Source Type: news

ICMR teams up with Bharat Biotech to develop COVID-19 vaccine
The vaccine will be developed using the virus strain isolated at the ICMR's National Institute of Virology (NIV), Pune, a statement said. The strain has been successfully transferred from NIV to BBIL, it added. The death toll due to COVID-19 rose to 1,981 and the number of cases climbed to 59,662 in the country on Saturday, according to the Union Health Ministry. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 8, 2020 Category: Pharmaceuticals Source Type: news

Chinese drugmaker in talks to test virus vaccine globally
With China having largely curbed its growth of new infections, its drugmakers will need to seek international cooperation to test their vaccine candidates in other countries — a task that may be complicated by tensions between China and some nations, especially the US, over how and where the virus originated. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 7, 2020 Category: Pharmaceuticals Source Type: news

Dr Reddy's gets USFDA inspection closure report for Srikakulam plant
The US Food and Drug Administration (USFDA) had issued a warning letter to the facility in November, 2015, after inspecting it in 2014. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 7, 2020 Category: Pharmaceuticals Source Type: news

Biocon gets establishment inspection report from USFDA for Bengaluru plant
The EIR has been closed with a voluntary action indicated (VAI) classification for the observations, it added. As per the USFDA, a VAI means that objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - May 7, 2020 Category: Pharmaceuticals Source Type: news